ATLC vs NCDL
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ATLC's Piotroski F-Score of 4 indicates a borderline stable financial health, falling short of strong fundamentals. The absence of an Altman Z-Score raises concern about bankruptcy risk, particularly given a dangerously high Debt/Equity ratio of 10.16. Despite strong profitability metrics—21.93% profit margin and 19.72% ROE—the company trades at a forward P/E of just 3.64, suggesting market skepticism or deep value positioning. The stock is significantly undervalued relative to its Graham Number ($71.88) and intrinsic value ($166.09), but this may reflect underlying financial fragility. Analysts remain optimistic with a strong_buy consensus, though insider selling and weak technical momentum temper enthusiasm.
NCDL exhibits severe fundamental deterioration, highlighted by a critical Piotroski F-Score of 0/9, indicating weakness across all health dimensions. The company is currently trading at $14.63, a significant premium to its growth-based intrinsic value of $9.10. Most concerning is the unsustainable dividend payout ratio of 138.46%, suggesting the company is returning more capital than it earns. Despite a 'Buy' analyst consensus, the combination of negative YoY EPS growth (-20%) and a bearish technical trend suggests a high-risk profile.
Compare Another Pair
Related Comparisons
ATLC vs NCDL: Head-to-Head Comparison
This page compares Atlanticus Holdings Corporation (ATLC) and Nuveen Churchill Direct Lending Corp. (NCDL) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.